The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma
Name: SCT-I10A+chemo
Name: Placebos+chemo
Description: OS is defined as time from first dose of SCT-I10A until the date of death from any cause
Measure: Overall survival Time: 1 yearDescription: PFS is defined as the time from first dose of SCT-I10A until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criter
Measure: Progression free survival Time: 1 yearDescription: ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment
Measure: Objective response rate Time: 1 yearAllocation: Randomized
Parallel Assignment
There is one SNP
SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial. --- I10A ---
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma Overall survival. --- I10A ---
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma Overall survival. --- I10A --- --- I10A ---
OS is defined as time from first dose of SCT-I10A until the date of death from any cause. --- I10A ---
PFS is defined as the time from first dose of SCT-I10A until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criter. --- I10A ---
Head and Neck Squamous Cell Carcinoma Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck This is a Phase III, multicenter, randomized, double-blinded trial designed to evaluate Overall survival (OS) of SCT-I10A combined with standard chemotherapy in patients living with Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma --- I10A ---